Filing Analysis
Ovid Therapeutics Inc. reported the results of its annual meeting of stockholders held on June 10, 2026. Stockholders elected a director, approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 10, 2026.
- Quorum achieved with 130,958,928 shares (75.7%) present or represented by proxy out of 173,037,131 outstanding shares.
- Jeremy M. Levin was elected as a director for a three-year term.
- Executive compensation was approved on an advisory basis (84.5M votes 'For').
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Ovid Therapeutics Inc. announced the appointment of Anna Greka, M.D., Ph.D., as a Class III director effective June 15, 2026. This appointment increases the total size of the Board of Directors to seven members.
📋 Key Facts
- Anna Greka, M.D., Ph.D., appointed as Class III director with a term expiring at the 2029 annual meeting.
- Effective date of appointment is June 15, 2026.
- Dr. Greka will serve on the Compensation Committee and the Science and Technology Committee.
- Dr. Greka is a Professor of Medicine at Harvard Medical School and holds leadership roles at the Broad Institute of MIT and Harvard.
- Board size increased to seven directors.
Ovid Therapeutics Inc. reported its first quarter 2026 financial results and provided business updates on May 12, 2026. The information was furnished as part of a routine quarterly earnings announcement.
📋 Key Facts
- The filing was made on May 12, 2026, covering the period ending March 31, 2026.
- The company furnished a press release as Exhibit 99.1 detailing Q1 2026 financial results.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Jeffrey Rona, Chief Business and Financial Officer, signed the report.
Ovid Therapeutics announced the full exercise of Series A Warrants from its October 2025 private placement, resulting in approximately $53.9 million in gross proceeds. The transaction involved the issuance of 33,597,860 common shares and 4,883,464 pre-funded warrants.
🚩 Red Flags
- Significant equity dilution resulting from the issuance of over 38 million shares/equivalents.
📋 Key Facts
- Series A Warrants expired on April 17, 2026.
- Total underlying shares involved were 38,481,325.
- Common stock exercise price was $1.40 per share.
- Pre-funded warrants exercise price was $1.399 per share.
- Total gross proceeds to the Company amounted to approximately $53.9 million.
- The warrants originated from a private placement conducted in October 2025.
Ovid Therapeutics entered into a $60 million PIPE financing agreement to issue common stock and pre-funded warrants. The proceeds are earmarked for the clinical expansion of its OV329 program and general research and development.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of approximately 29.8 million shares/warrants.
- The use of a PIPE (Private Investment in Public Equity) structure rather than a traditional public offering.
📋 Key Facts
- The PIPE financing involves the sale of 19,154,321 shares of common stock and 10,701,710 pre-funded warrants.
- Gross proceeds are expected to be $60.0 million before fees and expenses.
- The purchase price is $2.01 per share and $2.009 per pre-funded warrant (with a $0.001 exercise price).
- Funds will support the expansion of OV329 (a GABA-AT inhibitor) into tuberous sclerosis complex and infantile spasms indications.
- The company also reported Q4 and full year 2025 financial results and Phase 1 clearance for OV4071.